Norepinephrine for Vasoconstriction

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Alberta, Edmonton, Canada
Vasoconstriction+1 More
Norepinephrine - Drug
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This study aims to investigate sex differences in blood pressure control associated with exposure to acute hypoxia (low oxygen), and short term acclimatization to hypoxia at high altitude.

Eligible Conditions

  • Vasoconstriction
  • Vasodilation

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Vasoconstriction

Study Objectives

6 Primary · 0 Secondary · Reporting Duration: 1 hour 30 minutes

1 hour
Phentolamine
1 hour 30 minutes
Change in arterial blood flow
2 hours
Propranolol
20 minutes
Change in vascular conductance
3 minutes
Change in systolic, diastolic, and mean arterial blood pressure
Cold pressor test

Trial Safety

Safety Progress

1 of 3

Other trials for Vasoconstriction

Trial Design

2 Treatment Groups

High Altitude
1 of 2
Low Altitude
1 of 2
Experimental Treatment

20 Total Participants · 2 Treatment Groups

Primary Treatment: Norepinephrine · No Placebo Group · N/A

High AltitudeExperimental Group · 8 Interventions: Isometric Handgrip and Post-Exercise Circulatory Occlusion, Propranolol Hydrochloride, Sodium Nitroprusside, Cold Pressor Test, Phenylephrine Hydrochloride, Norepinephrine, Rhythmic Handgrip, Phentolamine Mesylate · Intervention Types: Other, Drug, Drug, Other, Drug, Drug, Other, Drug
Low AltitudeExperimental Group · 8 Interventions: Isometric Handgrip and Post-Exercise Circulatory Occlusion, Propranolol Hydrochloride, Sodium Nitroprusside, Cold Pressor Test, Phenylephrine Hydrochloride, Norepinephrine, Rhythmic Handgrip, Phentolamine Mesylate · Intervention Types: Other, Drug, Drug, Other, Drug, Drug, Other, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Propranolol Hydrochloride
2012
Completed Early Phase 1
~40
Sodium Nitroprusside
2018
Completed Phase 1
~200
Phenylephrine Hydrochloride
2019
N/A
~40
Norepinephrine
2014
Completed Phase 4
~2080

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 hour 30 minutes
Closest Location: University of Alberta · Edmonton, Canada
Photo of university of alberta hospital 1Photo of university of alberta hospital 2Photo of university of alberta hospital 3
2006First Recorded Clinical Trial
3 TrialsResearching Vasoconstriction
300 CompletedClinical Trials

Who is running the clinical trial?

University of AlbertaLead Sponsor
797 Previous Clinical Trials
368,796 Total Patients Enrolled
2 Trials studying Vasoconstriction
33 Patients Enrolled for Vasoconstriction
Craig D Steinback, PhDPrincipal InvestigatorUniversity of Alberta
Sean van Diepen, MD, MScPrincipal InvestigatorUniversity of Alberta
2 Previous Clinical Trials
33 Total Patients Enrolled
2 Trials studying Vasoconstriction
33 Patients Enrolled for Vasoconstriction

Eligibility Criteria

Age 18 - 65 · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must be between the ages of 18 and 50
You have no known medical history of cardiovascular, respiratory, nervous system, or metabolic disease.
You are female and pre-menopausal.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.